CA3199351A1 - Inhibitor of fibrosis progression - Google Patents
Inhibitor of fibrosis progressionInfo
- Publication number
- CA3199351A1 CA3199351A1 CA3199351A CA3199351A CA3199351A1 CA 3199351 A1 CA3199351 A1 CA 3199351A1 CA 3199351 A CA3199351 A CA 3199351A CA 3199351 A CA3199351 A CA 3199351A CA 3199351 A1 CA3199351 A1 CA 3199351A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrosis
- antibody
- seq
- receptor
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2020/044406 | 2020-11-30 | ||
| PCT/JP2020/044406 WO2022113316A1 (ja) | 2020-11-30 | 2020-11-30 | 線維化の進行抑制剤 |
| PCT/JP2021/043543 WO2022114165A1 (ja) | 2020-11-30 | 2021-11-29 | 線維化の進行抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3199351A1 true CA3199351A1 (en) | 2022-06-02 |
Family
ID=81754505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3199351A Pending CA3199351A1 (en) | 2020-11-30 | 2021-11-29 | Inhibitor of fibrosis progression |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240084020A1 (https=) |
| EP (1) | EP4252771A4 (https=) |
| JP (3) | JPWO2022113316A1 (https=) |
| KR (1) | KR20230114698A (https=) |
| CN (1) | CN116829187A (https=) |
| AU (1) | AU2021385871A1 (https=) |
| CA (1) | CA3199351A1 (https=) |
| CL (1) | CL2023001460A1 (https=) |
| IL (1) | IL303159A (https=) |
| MX (1) | MX2023006164A (https=) |
| TW (1) | TW202237182A (https=) |
| WO (2) | WO2022113316A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| MX2022005654A (es) | 2019-11-20 | 2022-06-22 | Chugai Pharmaceutical Co Ltd | Preparacion que contiene anticuerpo. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5954916B1 (ja) * | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
-
2020
- 2020-11-30 WO PCT/JP2020/044406 patent/WO2022113316A1/ja not_active Ceased
- 2020-11-30 JP JP2021531123A patent/JPWO2022113316A1/ja not_active Withdrawn
-
2021
- 2021-11-29 IL IL303159A patent/IL303159A/en unknown
- 2021-11-29 AU AU2021385871A patent/AU2021385871A1/en active Pending
- 2021-11-29 EP EP21898137.1A patent/EP4252771A4/en active Pending
- 2021-11-29 MX MX2023006164A patent/MX2023006164A/es unknown
- 2021-11-29 TW TW110144377A patent/TW202237182A/zh unknown
- 2021-11-29 US US18/038,460 patent/US20240084020A1/en active Pending
- 2021-11-29 CN CN202180091901.4A patent/CN116829187A/zh active Pending
- 2021-11-29 CA CA3199351A patent/CA3199351A1/en active Pending
- 2021-11-29 KR KR1020227005324A patent/KR20230114698A/ko active Pending
- 2021-11-29 JP JP2022500682A patent/JPWO2022114165A1/ja not_active Withdrawn
- 2021-11-29 WO PCT/JP2021/043543 patent/WO2022114165A1/ja not_active Ceased
-
2022
- 2022-04-15 JP JP2022067622A patent/JP7802601B2/ja active Active
-
2023
- 2023-05-22 CL CL2023001460A patent/CL2023001460A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230114698A (ko) | 2023-08-01 |
| EP4252771A4 (en) | 2024-10-23 |
| JP2022095913A (ja) | 2022-06-28 |
| TW202237182A (zh) | 2022-10-01 |
| MX2023006164A (es) | 2023-07-28 |
| WO2022114165A1 (ja) | 2022-06-02 |
| CN116829187A (zh) | 2023-09-29 |
| IL303159A (en) | 2023-07-01 |
| JPWO2022114165A1 (https=) | 2022-06-02 |
| WO2022113316A1 (ja) | 2022-06-02 |
| US20240084020A1 (en) | 2024-03-14 |
| AU2021385871A9 (en) | 2024-05-02 |
| JP7802601B2 (ja) | 2026-01-20 |
| AU2021385871A1 (en) | 2023-06-22 |
| CL2023001460A1 (es) | 2023-12-01 |
| JPWO2022113316A1 (https=) | 2022-06-02 |
| EP4252771A1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11926671B2 (en) | Antibodies and polypeptides directed against CD127 | |
| AU2015231777B2 (en) | IL-21 antibodies | |
| CN115335120B (zh) | 用于治疗和/或预防冠状病毒诱导的急性呼吸窘迫综合征的抑制masp-2的方法 | |
| KR20140084043A (ko) | 대식세포 활성화의 조절 | |
| US20110086906A1 (en) | Methods for treatment or prevention of diseases associated with functional disorder of regulatory t cells | |
| NZ562333A (en) | Methods for treating and preventing fibrosis resulting from wound healing using interleukin 21 / interleukin 21R antagonists | |
| EP4252771A1 (en) | Inhibitor of fibrosis progression | |
| Lee et al. | Poly-γ-glutamic acid suppresses osteoclastogenesis in human osteoclast precursors and prevents joint damage in a collagen-induced murine arthritis model | |
| EA050619B1 (ru) | Ингибитор прогрессирования фиброза | |
| HK40092050A (zh) | 纤维化进展的抑制剂 | |
| JP7576847B2 (ja) | 免疫応答抑制剤 | |
| Alvarado et al. | Dual targeting of mast cells and TSLP with a bispecific antibody | |
| US20250154238A1 (en) | Methods and compositions for treating and preventing fibrosis | |
| WO2024011946A1 (en) | Polypeptide dimers for the treatment of systemic sclerosis | |
| WO2012002775A2 (ko) | 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 | |
| Potomkina et al. | Lishchuk-Yakymovych K., Chopyak V. | |
| EA041126B1 (ru) | Антитела и полипептиды, направленные против cd127 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241119 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241119 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241119 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251117 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20251125 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251125 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260120 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260120 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260120 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260121 |